IL17A and COVID-19: The ROC curve showed that an elevated IL-17 level greater than 187.9 ng/mL predicted poor clinical outcomes in COVID-19 patients with higher probability of disease progression and severe complications (AUC = 0.685, 95% CI = 0.575 to 0.781, p = 0.0022 with a sensitivity of 63.16%, specificity of 76.60%, PPV of 68.5709%, NPV of 72.0071%).